Skip to main content

Advertisement

Table 2 Over active bladder and urinary incontinence symptoms frequency as recorded from micturition diaries

From: Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial

Variable Placebo (mean ± SD) UROX (mean ± SD) OR (95% CI) Placebo vs treatment
Day frequency (n/day)
 Week 0 11.57 ± 1.79 11.53 ± 1.54 0.95 (0.33 to 2.73)
 Week 2 10.80 ± 2.44 8.94 ± 2.28 0.07 (0.04 to 0.13)*
 Week 4 10.60 ± 2.42 8.42 ± 2.46 0.04 (0.02 to 0.08)*
 Week 8 10.95 ± 2.47 7.69 ± 2.15 0.01 (0.01 to 0.02)*
Nocturia (n/day)
 Week 0 3.39 ± 1.52 4.02 ± 1.62 3.59 (1.39 to 9.21)*
 Week 2 2.94 ± 1.37 3.18 ± 1.72 0.40 (0.24 to 0.69)*
 Week 4 2.92 ± 1.30 2.70 ± 1.52 0.14 (0.08 to 0.24)*
 Week 8 3.14 ± 1.36 2.16 ± 1.49 0.03 (0.02 to 0.05)*
Urgency (n/day)
 Week 0 4.34 ± 2.89 3.80 ± 1.82 0.67 (0.23 to 1.94)
 Week 2 3.65 ± 2.62 2.32 ± 2.09 0.16 (0.09 to 0.27)*
 Week 4 3.52 ± 2.68 1.88 ± 2.25 0.08 (0.04 to 0.13)*
 Week 8 3.93 ± 2.87 1.49 ± 2.31 0.02 (0.01 to 0.03)*
Urgency Incontinence (n/day)
 Week 0 2.71 ± 2.68 2.79 ± 1.50 1.70 (0.53 to 5.40)
 Week 2 2.32 ± 1.54 1.85 ± 1.78 0.19 (0.09 to 0.40)*
 Week 4 1.82 ± 1.33 1.53 ± 2.41 0.19 (0.09 to 0.40)*
 Week 8 2.44 ± 2.38 1.24 ± 2.49 0.04 (0.02 to 0.09)*
Stress Incontinence (n/day)
 Week 0 2.19 ± 1.50 2.13 ± 1.14 0.97 (0.11 to 8.65)
 Week 2 1.70 ± 1.49 1.27 ± 1.29 0.30 (0.07 to 1.29)
 Week 4 1.85 ± 1.29 0.77 ± 0.94 0.06 (0.01 to 0.25)*
 Week 8 2.04 ± 1.51 0.73 ± 0.87 0.03 (0.01 to 0.15)*
Total Incontinence (n/day)
 Week 0 2.95 ± 2.65 3.31 ± 2.12 1.97 (0.65 to 5.98)
 Week 2 2.56 ± 1.62 2.20 ± 2.09 0.23 (0.11 to 0.45)*
 Week 4 2.13 ± 1.42 1.74 ± 2.68 0.14 (0.07 to 0.27)*
 Week 8 2.70 ± 2.25 1.38 ± 2.73 0.03 (0.01 to 0.06)*
  1. OR (95% CI): odds ratio and 95% confidence interval for difference between the two treatments (includes participants who did not complete the study); Comparison made as change from baseline between the two conditions. Holm estimation test was used to adjust p-values for repeated measures
  2. *Significantly different between the two treatments at the specific time; Number of participants assessed for each symptom were according to if their baseline measures matched the inclusion criteria (see Table 2 for the exact number of participants)